Improved adenoviral vector for vascular gene therapy: Beneficial effects on vascular function and inflammation

Circulation Research

Volumn 88, Issue 9, 2001, Pages 911-917

  Qian, Hu Sheng ^a   Channon, Keith ^b   Neplioueva, Valentina ^a   Wang, Qing ^c   Finer, Mitchell ^c   Tsui, Lisa ^c   George, Samuel E ^a   McArthur, James ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CELL GENESYS INC   (United States)

Author keywords

Adenoviral vectors; Vascular gene therapy

Indexed keywords

BETA GALACTOSIDASE; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; GENE DELETION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; TRANSGENE; VASCULAR ENDOTHELIUM; VASOMOTOR REFLEX;

EID: 0035844088     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/hh0901.090926     Document Type: Article

References (36)

1. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. Gene therapy for vascular smooth muscle cell proliferation after arterial injury [see comments]. Science. 1994;265:781-784.
2. Claudio P, Fratta L, Farina F, Howard C, Stassi G, Numata S, Pacilio C, Davis A, Lavitrano M, Volpe M, Wilson J, Trimarco B, Giordano A, Condorelli G. Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty. Circ Res. 1999;85:1032-1039.
3. Macejak D, Lin H, Webb S, Chase J, Jensen K, Jarvis T, Leiden J, Couture L. Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo. J Virol. 1999;73:7745-7751.
4. Harrell RL, Rajanayagam S, Doanes AM, Guzman RJ, Hirschowitz EA, Crystal RG, Epstein SE, Finkel T. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation. 1997;96:621-627.
5. Chang MW, Ohno T, Gordon D, Lu MM, Nabel GJ, Nabel EG, Leiden JM. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery. Mol Med. 1995;1:172-181.
6. Chang M, Barr E, Lu M, Barton K, Leiden J. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;96:2260-2268.
7. Chang M, Barr E, Seltzer J, Jiang Y, Nabel G, Nabel E, Parmacek M, Leiden J. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-521.
8. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A. 1994;91:10732-10736.
9. Waugh J, Kattash M, Li J, Yuksel E, Kuo M, Lussier M, Weinfeld A, Saxena R, Rabinovsky E, Thung S, Woo S, Shenaq S. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci U S A. 1999;96:1065-1070.
10. Mann MJ, Gibbons GH, Tsao PS, von der Leyen HE, Cooke JP, Buitrago R, Kernoff R, Dzau VJ. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest. 1997; 99:1295-1301.
11. Mann M, Whittemore A, Donaldson M, Belkin M, Conte M, Polak J, Gray E, Ehsan A, DellAcqua G, Dzau V. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 1999;354:1493-1498.
12. Channon K, Fulton G, Gray J, Annex B. Shetty G, Blazing M, Peters K, Hagen P, George S. Efficient adenoviral gene transfer to early venous bypass grafts: comparison with native vessels. Cardiovasc Res. 1997;35:505-513.
13. Qian H, Neplioueva V, Shetty G, Channon K, George S. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation. 1999;99:2979-2982.
14. George S, Johnson J, Angelini G, Newby A, Baker A. Adenovirus-mediated gene transfer of the human TIMP- 1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther. 1998;9:867-877.
15. George S, Lloyd C, Angelini G, Newby A, Baker A. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation. 2000;101:296-304.
16. Bai H, Morishita R. Kida I, Yamakawa T, Zhang W, Aoki M, Matsushita H, Noda A, Nagai R, Kaneda Y, Higaki J, Ogihara T, Sawa Y, Matsuda H. Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. Gene Ther. 1998;5:761-769.
17. Newman K, Dunn P, Owens J, Schulick A, Virmani R, Sukhova G, Libby P, Dichek D. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest. 1995;96:2955-2965.
18. Channon K, Qian H, Youngblood S, Olmez E, Shetty G, Neplioueva V, Blazing M, George S. Acute host-mediated endothelial injury after adenoviral gene transfer in normal rabbit arteries: impact on transgene expression and endothelial function. Circ Res. 1998;82:1253-1262.
19. Yang Y, Haecker S, Su Q, Wilson J. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet. 1996;5:1703-1712.
20. Jooss K, Turka L, Wilson J. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Ther. 1998;5:309-319.
21. Jooss K, Ertl H, Wilson J. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol. 1998;72:945-2954.
22. Kay M, Meuse L, Gown A, Linsley P, Hollenbaugh D. Aruffo A, Ochs H, Wilson C. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A. 1997;94:4686-4691.
23. Chirmule N, Raper S, Burkly L, Thomas D, Tazelaar J, Hughes J, Wilson J. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions. J Virol. 2000;74:3345-3352.
24. Chirmule N, Truneh A, Haecker S, Tazelaar J, Gao G, Raper S, Hughes J, Wilson J. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody. J Immunol. 1999;163:448-455.
25. Krougliak V, Graham F. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther. 1995;6:1575-1586.
26. Mitani K, Graham F, Caskey C, Kochanek S. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Proc Natl Acad Sci U S A. 1995;92:3854-3858.
27. Gao G, Yang Y, Wilson J. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996;70:8934-8943.
28. Engelhardt J, Ye X, Doranz B, Wilson J. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A. 1994;91:6196-6200.
29. Brough D, Lizonova A, Hsu C, Kulesa V, Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol. 1996;70:6497-6501.
30. Wang Q, Jia X, Finer M. A packaging cell line for propagation of recombinant adenovirus vectors containing two lethal gene-region deletions. Gene Ther. 1995;2:775-783.
31. Wang Q, Finer M. Second-generation adenovirus vectors. Nat Med. 1996;2:714-716.
32. Wang Q, Greenburg G, Bunch D, Farson D, Finer M. Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Ther. 1997;4:393-400.
33. Morsy M, Gu M, Motzel S, Zhao J, Lin Q, Su Q, Allen H, Ranlin L, Parks R, Graham F, Kochanek S, Bett A, Caskey C. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci U S A. 1998;95:7866-7871.
34. Parks R, Chen L, Anton M, Sankar U, Rudnicki M, Graham F. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A. 1996;93:13565-13570.
35. Tripathy S, Black H, Goldwasser E, Leiden J. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat Med. 1996;2:545-550.
36. Dedieu J, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud J, Aubailly N, Orsini C, Guillaume J, Opolon P, Delaere P, Perricaudet M, Yeh P. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol. 1997;71:4626-637.